selected publications
- Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth. The Journal of clinical investigation. 2023 Academic Article GET IT
-
CXCR7 as a novel therapeutic target for advanced prostate cancer.
Oncogene.
2023
Review
GET IT
Times cited: 8 -
FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
Oncogene.
2022
Academic Article
GET IT
Times cited: 7 -
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.
Nature genetics.
2022
Academic Article
GET IT
Times cited: 35 - Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. 2020 GET IT
-
Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
Cancer research.
2019
Academic Article
GET IT
Times cited: 86 -
Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer.
Asian journal of andrology.
2019
Review
GET IT
Times cited: 22